{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:44Z","timestamp":1793325764428,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Similar patients experienced almost three-fold differences in biopsy timing depending on which physician they saw.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Glucocorticoid prescribing varied meaningfully by physician after adjustment for clinical and biopsy features.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Practice patterns in the management of IgA nephropathy (IgAN) vary but the extent of physician-level variability in key decisions, such as kidney biopsy and glucocorticoid use, is unknown. Understanding variability in clinical practice provides essential context for knowledge translation as new evidence and guidelines emerge for the treatment of IgAN. We hypothesized that time to biopsy and likelihood of glucocorticoid use would vary significantly by physician.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based cohort study of adults with biopsy-proven IgAN in Manitoba, Canada (2002\u20132021). Linear mixed-effects models were used to examine factors associated with time from urinary abnormality to kidney biopsy, and logistic mixed models were used to assess the likelihood of glucocorticoid prescription. Models included random intercepts for physician to quantify between-physician variability using the intraclass correlation coefficient (ICC), median time ratio, and median odds ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 380 patients managed by 38 physicians, the physician-level ICC for time to biopsy was 0.31, indicating that nearly one third of the total variability in time to biopsy was attributable to between-physician differences. The corresponding median time ratio was 2.65, representing a nearly three-fold difference in time to biopsy between two otherwise similar patients managed by different physicians. For glucocorticoid prescription, the ICC was 0.07, indicating 7% of the variability was attributable to physician practice. The median odds ratio was 1.59, indicating that two otherwise similar patients could have 59% different odds of being prescribed glucocorticoids depending on which physician managed their care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is one of the first studies to quantify between-physician variability in IgAN care. Substantial between-physician variability exists in the timing of biopsy and use of immunosuppression in IgAN. These findings highlight opportunities for targeted knowledge translation to promote timely, equitable, and evidence-aligned care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001232","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:02:10Z","timestamp":1778774530000},"page":"1854-1863","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Physician Variability in Time to Kidney Biopsy and Glucocorticoid Prescription in IgA Nephropathy"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-978X","authenticated-orcid":false,"given":"Bryce","family":"Barr","sequence":"first","affiliation":[{"name":"Department of Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-3685","authenticated-orcid":false,"given":"Hailey","family":"Hildebrand","sequence":"additional","affiliation":[{"name":"Department of Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-0262","authenticated-orcid":false,"given":"Ian W.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"2","key":"B1-20261029","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B2-20261029","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B3-20261029","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B4-20261029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B5-20261029","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B6-20261029","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"issue":"5","key":"B7-20261029","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"B8-20261029","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int."},{"issue":"6","key":"B9-20261029","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B10-20261029","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"B11-20261029","doi-asserted-by":"crossref","first-page":"sfae230","DOI":"10.1093\/ckj\/sfae230","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort","volume":"17","author":"Stamellou","year":"2024","journal-title":"Clin Kidney J."},{"issue":"19","key":"B12-20261029","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA."},{"issue":"10405","key":"B13-20261029","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet."},{"issue":"6","key":"B14-20261029","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med."},{"issue":"2","key":"B15-20261029","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"1","key":"B16-20261029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"4S","key":"B17-20261029","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int."},{"key":"B18-20261029","doi-asserted-by":"crossref","first-page":"20543581231178963","DOI":"10.1177\/20543581231178963","article-title":"The development of a comprehensive clinicopathologic registry for glomerular diseases using natural language processing","volume":"10","author":"Barr","year":"2023","journal-title":"Can J kidney Health Dis."},{"issue":"3","key":"B19-20261029","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jamia\/ocx078","article-title":"Assessing the quality of administrative data for research: a framework from the Manitoba Centre for Health Policy","volume":"25","author":"Smith","year":"2018","journal-title":"J Am Med Inform Assoc."},{"issue":"19","key":"B20-20261029","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"5","key":"B21-20261029","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.kint.2016.06.020","article-title":"The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases","volume":"90","author":"Hogan","year":"2016","journal-title":"Kidney Int."},{"issue":"4","key":"B22-20261029","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/ndt\/gfr708","article-title":"The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients","volume":"27","author":"Smith","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B23-20261029","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2008.04.014","article-title":"A comparison of urinary albumin-total protein ratio to phase-contrast microscopic examination of urine sediment for differentiating glomerular and nonglomerular bleeding","volume":"52","author":"Ohisa","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"B24-20261029","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s12889-015-1992-y","article-title":"Development of a Canadian socioeconomic status index for the study of health outcomes related to environmental pollution","volume":"15","author":"Chan","year":"2015","journal-title":"BMC Public Health."},{"issue":"3","key":"B25-20261029","first-page":"433","article-title":"The Canadian chronic disease surveillance system: a model for collaborative surveillance","volume":"3","author":"Lix","year":"2018","journal-title":"Int J Popul Data Sci."},{"issue":"12","key":"B26-20261029","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"23","key":"B27-20261029","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"B28-20261029","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/jech.2004.029454","article-title":"A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena","volume":"60","author":"Merlo","year":"2006","journal-title":"J Epidemiol Community Health."},{"issue":"3","key":"B29-20261029","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.0006-341X.2000.00909.x","article-title":"Interpreting parameters in the logistic regression model with random effects","volume":"56","author":"Larsen","year":"2000","journal-title":"Biometrics."},{"issue":"6","key":"B30-20261029","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ckj\/sfu104","article-title":"The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists","volume":"7","author":"Barbour","year":"2014","journal-title":"Clin Kidney J."},{"issue":"7","key":"B31-20261029","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s40620-025-02313-6","article-title":"Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts","volume":"38","author":"Goggins","year":"2025","journal-title":"J Nephrol."},{"issue":"5","key":"B32-20261029","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1037\/0021-9010.88.5.879","article-title":"Common method biases in behavioral research: a critical review of the literature and recommended remedies","volume":"88","author":"Podsakoff","year":"2003","journal-title":"J Appl Psychol."},{"issue":"8","key":"B33-20261029","doi-asserted-by":"crossref","first-page":"e0272662","DOI":"10.1371\/journal.pone.0272662","article-title":"Quality and variation of care for chronic kidney disease in Swiss general practice: a retrospective database study","volume":"17","author":"J\u00e4ger","year":"2022","journal-title":"PLoS One."},{"issue":"10","key":"B34-20261029","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2215\/CJN.12321213","article-title":"Variation in the level of eGFR at dialysis initiation across dialysis facilities and geographic regions","volume":"9","author":"Sood","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B35-20261029","doi-asserted-by":"crossref","first-page":"e094811","DOI":"10.1136\/bmjopen-2024-094811","article-title":"Interpractice variability in antibiotic prescribing for acute respiratory tract infections: a cross-sectional study of Australian early-career general practitioners","volume":"15","author":"Turner","year":"2025","journal-title":"BMJ Open."},{"issue":"1","key":"B38-20261029","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.0000000796","article-title":"Predictive value of the Oxford classification for the effect of glucocorticoid therapy in IgA nephropathy","volume":"37","author":"Shi","year":"2026","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B39-20261029","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int."},{"issue":"5","key":"B40-20261029","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00281-021-00884-7","article-title":"Is IgA nephropathy the same disease in different parts of the world?","volume":"43","author":"Zhang","year":"2021","journal-title":"Semin Immunopathol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:01:33Z","timestamp":1793282493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001232"}},"subtitle":["A Population-Based Cohort Study"],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001232","relation":{},"ISSN":["2641-7650","2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"},{"value":"2641-7650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2026-02-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}